Using information from more than 1,100 MDR-TB cases across nine countries, a CDC researcher also found that doing baseline drug susceptibility testing on a patient beforehand improved results. This type of testing helps to determine which treatments might help fight the infection, and selecting a regimen based on those results increased the likelihood of effectiveness by 65 percent. Adding drugs to the regimen that had not gone through susceptibility testing only benefited the patient if they were already receiving at least three drugs known to be effective.
Although the study was observational and based on patient data across many cases that didn’t account for shared characteristics that could affect disease outcome or relapse information, the authors conclude that a change to the current MDR-TB WHO treatment guidelines could be beneficial. In general, more widespread use of rapid, high-quality drug susceptibility testing would likely help clinicians to design more effective regimens for individual patients, they wrote in a news release.
More articles on infection control:
Researchers create tool to identify plague hotspots in the US
Top 10 infection control stories of 2015
ZDoggMD delivers holiday-themed ‘It’s Beginning to Look a Lot Like Sepsis’ music video
